Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Abbv - What They Never Told You

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks

How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks

AbbVie has underperformed the healthcare peers over the past year, and analysts remain very optimistic about the stock’s outlook.

MarketBeat Week in Review – 08/03 - 08/07

MarketBeat Week in Review – 08/03 - 08/07

A weekly roundup of MarketBeat analysis covering earnings from AbbVie, AMD, Palantir, Meta, Reddit, SpaceX and others, plus upcoming CPI and PPI inflation data.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

What Are Wall Street Analysts' Target Price for AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

AbbVie Earnings Preview: What to Expect

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

inkl

Read news from The Economist, FT, and more,
with one subscription

AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.

AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.

Apogee’s rally may be over, but AbbVie’s upside from the deal could just be getting started.

The $11 Billion Reason Abbvie Stock Is Up Today

The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.

AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.

Q1 earnings show this Dividend King still looks built for the long term.

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie's early 2026 price pullback is an irresistable opportunity for buy-and-hold investors looking for income and compounding opportunities.

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

These three Dividend Aristocrats offer yields above 3% and a history of consistent dividend growth, making them strong choices to help stay ahead of inflation.

Get all your
news in one place.

100's of premium titles.
One news app.

What You Need to Know Ahead of AbbVie’s Earnings Release

AbbVie will release its first-quarter earnings this month, and analysts anticipate a double-digit bottom-line growth.

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

AbbVie is on track to grow, drive cash flow, and pay a healthy dividend for the long term: institutions and analysts are accumulating this stock.

AbbVie Stock: Analyst Estimates & Ratings

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

The 3 Most Reliable Dividend Stocks to Buy for Years to Come

These three dividend stocks are long-term winners with dependable payouts.

Get all your
news in one place.

100's of premium titles.
One news app.

AbbVie Call Options Spike 2,599%: Tracking the Big Bet

Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and reaches a federal agreement.

What to Expect From AbbVie's Next Quarterly Earnings Report

AbbVie will release its fourth-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

3 Dividend Growth Stocks Analysts Are Upgrading for 2026

United Parcel Service, PepsiCo, and AbbVie are healthy dividend payers whose analyst trends support an outlook for price strength in 2026.

3 Dividend Kings Delivering Generational Income & Market-Beating Returns

3 top-performing Dividend Kings of 2025 based on their Year-to-Date percent change.

AbbVie’s (ABBV) Options Flow Implies That the Smart Money Could Be Up to Something

An intriguing quant signal combined with shifting sentiment in the derivatives market opens the possibility toward a bullish trade for ABBV stock.

Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul

AbbVie, McDonald’s, and Walmart offer growth, rising dividends, and valuation upside as investors seek blue-chip stability heading into 2026

1 2 3 4 5

People

Jeffrey Neal Johnson

Marc Lichtenfeld

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

British Airways

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play